Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial
| Autor: | Dickson W. L. Wong, Kathryn C.B. Tan, J. C. K. Leung, Loretta Y.Y. Chan, Gary Chi Wang Chan, Alfred S K Kwong, Yibin Feng, Benjamin J. Cowling, Tai Pang Ip, Kar Neng Lai, Kam Wa Chan, Wai Han Yiu, Yang Liu, Sydney C.W. Tang, Sing Leung Lui |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Pediatrics 030232 urology & nephrology Pilot Projects Type 2 diabetes law.invention Diabetic nephropathy 0302 clinical medicine Randomized controlled trial law Protocol Diabetic Nephropathies 030212 general & internal medicine Medicine Chinese Traditional Precision Medicine Aged 80 and over glomerular filtration rate Renal Medicine clinical trial General Medicine Middle Aged Institutional review board Treatment Outcome Research Design Creatinine Hong Kong Female medicine.symptom pragmatic Adult medicine.medical_specialty albuminuria 03 medical and health sciences Diabetes mellitus medicine Humans Aged Glycated Hemoglobin Integrative Medicine Chinese medicine business.industry medicine.disease Clinical trial Diabetes Mellitus Type 2 Albuminuria Patient Compliance business Drugs Chinese Herbal Kidney disease |
| Zdroj: | BMJ Open |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2015-010741 |
| Popis: | Introduction Diabetes mellitus and diabetic nephropathy (DN) are prevalent and costly to manage. DN is the leading cause of end-stage kidney disease. Conventional therapy blocking the renin–angiotensin system has only achieved limited effect in preserving renal function. Recent observational data show that the use of Chinese medicine (CM), a major form of traditional medicine used extensively in Asia, could reduce the risk of end-stage kidney disease. However, existing clinical practice guidelines are weakly evidence-based and the effect of CM remains unclear. This trial explores the effect of an existing integrative Chinese–Western medicine protocol for the management of DN. Objective To optimise parameters and assess the feasibility for a subsequent phase III randomised controlled trial through preliminary evaluation on the effect of an adjuvant semi-individualised CM treatment protocol on patients with type 2 diabetes with stages 2–3 chronic kidney disease and macroalbuminuria. Methods and analysis This is an assessor-blind, add-on, randomised, controlled, parallel, multicentre, open-label pilot pragmatic clinical trial. 148 patients diagnosed with DN will be recruited and randomised 1:1 to a 48-week additional semi-individualised CM treatment programme or standard medical care. Primary end points are the changes in estimated glomerular filtration rate and spot urine albumin-to-creatinine ratio between baseline and treatment end point. Secondary end points include fasting blood glucose, glycated haemoglobin, brain natriuretic peptide, fasting insulin, C peptide, fibroblast growth factor 23, urinary monocyte chemotactic protein-1, cystatin C, nephrin, transforming growth factor-β1 and vascular endothelial growth factor. Adverse events are monitored through self-completed questionnaire and clinical visits. Outcomes will be analysed by regression models. Enrolment started in July 2015. Ethics and registration This protocol is approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (reference number UW 14-301). Trial registration number NCT02488252. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|